IntroductionAccurately predicting Alzheimers Disease (AD) progression is useful for clinical care. The 2019 TADPOLE (The Alzheimers Disease Prediction Of Longitudinal Evolution) challenge evaluated 92 algorithms from 33 teams worldwide. Unlike typical clinical prediction studies, TADPOLE accommodates (1) variable number of observed timepoints across patients, (2) missing data across modalities and visits, and (3) prediction over an open-ended time horizon, which better reflects real-world data. However, TADPOLE only used the Alzheimers Disease Neuroimaging Initiative (ADNI) dataset, so how well top algorithms generalize to other cohorts remains unclear. MethodsWe tested five algorithms in three external datasets covering 2,312 participants and 13,200 timepoints. The algorithms included FROG, the overall TADPOLE winner, which utilized a unique Longitudinal-to-Cross-sectional (L2C) transformation to convert variable-length longitudinal histories into feature vectors of the same length across participants (i.e., same-length feature vectors). We also considered two FROG variants. One variant unified all XGBoost models from the original FROG with a single feedforward neural network (FNN), which we referred to as L2C-FNN. We also included minimal recurrent neural networks (MinimalRNN), which was ranked second at publication time, as well as AD Course Map (AD-Map), which outperformed MinimalRNN at publication time. All five models - three FROG variants, MinimalRNN and AD-Map - were trained on ADNI and tested on the external datasets. ResultsL2C-FNN performed the best overall. In the case of predicting cognition and ventricle volume, L2C-FNN and AD-Map were the best. For clinical diagnosis prediction, L2C-FNN was the best, while AD-Map was the worst. L2C-FNN also maintained its edge over other models, regardless of the number of observed timepoints, and regardless of the prediction horizon from 0 to 6 years into the future. ConclusionsL2C-FNN shows strong potential for both short-term and long-term dementia progression prediction. Pretrained ADNI models are available: https://github.com/ThomasYeoLab/CBIG/tree/master/stable_projects/predict_phenotypes/Zhang2025_L2CFNN.

Focal cortical dysplasia (FCD) is a common pathology for pharmacoresistant focal epilepsy, yet detection of FCD on clinical MRI is challenging. Magnetic resonance fingerprinting (MRF) is a novel quantitative imaging technique providing fast and reliable tissue property measurements. The aim of this study was to develop an MRF-based deep-learning (DL) framework for whole-brain FCD detection. We included patients with pharmacoresistant focal epilepsy and pathologically/radiologically diagnosed FCD, as well as age-matched and sex-matched healthy controls (HCs). All participants underwent 3D whole-brain MRF and clinical MRI scans. T1, T2, gray matter (GM), and white matter (WM) tissue fraction maps were reconstructed from a dictionary-matching algorithm based on the MRF acquisition. A 3D ROI was manually created for each lesion. All MRF maps and lesion labels were registered to the Montreal Neurological Institute space. Mean and SD T1 and T2 maps were calculated voxel-wise across using HC data. T1 and T2 <i>z</i>-score maps for each patient were generated by subtracting the mean HC map and dividing by the SD HC map. MRF-based morphometric maps were produced in the same manner as in the morphometric analysis program (MAP), based on MRF GM and WM maps. A no-new U-Net model was trained using various input combinations, with performance evaluated through leave-one-patient-out cross-validation. We compared model performance using various input combinations from clinical MRI and MRF to assess the impact of different input types on model effectiveness. We included 40 patients with FCD (mean age 28.1 years, 47.5% female; 11 with FCD IIa, 14 with IIb, 12 with mMCD, 3 with MOGHE) and 67 HCs. The DL model with optimal performance used all MRF-based inputs, including MRF-synthesized T1w, T1z, and T2z maps; tissue fraction maps; and morphometric maps. The patient-level sensitivity was 80% with an average of 1.7 false positives (FPs) per patient. Sensitivity was consistent across subtypes, lobar locations, and lesional/nonlesional clinical MRI. Models using clinical images showed lower sensitivity and higher FPs. The MRF-DL model also outperformed the established MAP18 pipeline in sensitivity, FPs, and lesion label overlap. The MRF-DL framework demonstrated efficacy for whole-brain FCD detection. Multiparametric MRF features from a single scan offer promising inputs for developing a deep-learning tool capable of detecting subtle epileptic lesions.

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in China, highlighting the importance of early diagnosis and ongoing monitoring for effective management. In recent years, hyperpolarized 129Xe MRI technology has gained significant clinical attention due to its ability to non-invasively and visually assess lung ventilation, microstructure, and gas exchange function. Its recent clinical approval in China, the United States and several European countries, represents a significant advancement in pulmonary imaging. This review provides an overview of the latest developments in hyperpolarized 129Xe MRI technology for COPD assessment in China. It covers the progress in instrument development, advanced imaging techniques, artificial intelligence-driven reconstruction methods, molecular imaging, and the application of this technology in both COPD patients and animal models. Furthermore, the review explores potential technical innovations in 129Xe MRI and discusses future directions for its clinical applications, aiming to address existing challenges and expand the technology's impact in clinical practice.

This study aims to determine the diagnostic performance of sub-5-min combined sixfold parallel imaging (PIx3)-simultaneous multislice (SMSx2)-accelerated deep learning (DL) super-resolution 3T knee MRI in children and adolescents. Children with painful knee conditions who underwent PIx3-SMSx2-accelerated DL super-resolution 3T knee MRI and arthroscopy between October 2022 and December 2023 were retrospectively included. Nine fellowship-trained musculoskeletal radiologists independently scored the MRI studies for image quality and the presence of artifacts (Likert scales, range: 1 = very bad/severe, 5 = very good/absent), as well as structural abnormalities. Interreader agreements and diagnostic performance testing was performed. Forty-four children (mean age: 15 ± 2 years; range: 9-17 years; 24 boys) who underwent knee MRI and arthroscopic surgery within 22 days (range, 2-133) were evaluated. Overall image quality was very good (median rating: 5 [IQR: 4-5]). Motion artifacts (5 [5-5]) and image noise (5 [4-5]) were absent. Arthroscopy-verified abnormalities were detected with good or better interreader agreement (κ ≥ 0.74). Sensitivity, specificity, accuracy, and AUC values were 100%, 84%, 93%, and 0.92, respectively, for anterior cruciate ligament tears; 71%, 97%, 93%, and 0.84 for medial meniscus tears; 65%, 100%, 86%, and 0.82 for lateral meniscus tears; 100%, 100%, 100%, and 1.00 for discoid lateral menisci; 100%, 95%, 96%, and 0.98 for medial patellofemoral ligament tears; and 55%, 100%, 98%, and 0.77 for articular cartilage defects. Clinical sub-5-min PIx3-SMSx2-accelerated DL super-resolution 3T knee MRI provides excellent image quality and high diagnostic performance for diagnosing internal derangement in children and adolescents.

The four-repeat (4R) tauopathies are a group of neurodegenerative diseases, including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and globular glial tauopathy (GGT). This study aimed to characterize spatiotemporal atrophy progression using structural magnetic resonance imaging (MRI) and to examine its relationship with clinical course and neuropathology in a cohort of autopsy-confirmed 4R tauopathies. The study included 85 autopsied patients (54 with PSP, 28 with CBD, and 3 with GGT) who underwent multiple 3T MRI scans, as well as neuropsychological, neurological, and speech/language examinations, and standardized postmortem neuropathological evaluations. An unsupervised machine-learning algorithm, Subtype and Stage Inference (SuStaIn), was applied to the cross-sectional brain volumes to estimate spatiotemporal atrophy patterns and data-driven subtypes and stages in each patient. The relationships among estimated subtypes, pathological diagnoses, and longitudinal changes in clinical testing were examined. The SuStaIn algorithm identified 2 distinct subtypes: (1) the subcortical subtype, in which atrophy progresses from the midbrain to the cortex, and (2) the cortical subtype, in which atrophy progresses from the frontal cortex to the subcortical regions. The subcortical subtype was more associated with typical PSP, whereas the cortical subtype was more associated with atypical PSP with a cortical distribution of pathology and CBD (p < 0.001). The cortical subtype had a faster rate of change on the PSP Rating Scale than the subcortical subtype (p < 0.05). SuStaIn analysis revealed 2 MRI-driven subtypes with distinct spatiotemporal atrophy patterns, clinical courses, and neuropathology. Our findings contribute to a comprehensive and improved understanding of disease progression and its relationship to tau pathology in 4R tauopathies. ANN NEUROL 2025.

Differentiating major depressive disorder (MDD) from bipolar disorder (BD) remains a significant clinical challenge, as both disorders exhibit overlapping symptoms but require distinct treatment approaches. Advances in voxel-based morphometry and surface-based morphometry have facilitated the identification of structural brain abnormalities that may serve as diagnostic biomarkers. This study aimed to explore the relationships between brain morphological features, such as grey matter volume (GMV) and cortical thickness (CT), and demographic and clinical variables in patients with MDD and BD and healthy controls (HC) using multivariate analysis methods. A total of 263 participants, including 120 HC, 95 patients with MDD and 48 patients with BD, underwent T1-weighted MRI. GMV and CT were computed for standardised brain regions, followed by multivariate partial least squares (PLS) regression to assess associations with demographic and diagnostic variables. Reductions in frontotemporal CT were observed in MDD and BD compared with HC, but distinct trends between BD and MDD were also detected for the CT of selective temporal, frontal and parietal regions. Differential patterns in cerebellar GMV were also identified, with lobule CI larger in MDD and lobule CII larger in BD. Additionally, BD showed the same trend as ageing concerning reductions in CT and posterior cerebellar and striatal GMV. Depression severity showed a transdiagnostic link with reduced frontotemporal CT. This study highlights shared and distinct structural brain alterations in MDD and BD, emphasising the potential of neuroimaging biomarkers to enhance diagnostic accuracy. Accelerated cortical thinning and differential cerebellar changes in BD may serve as targets for future research and clinical interventions. Our findings underscore the value of objective neuroimaging markers in increasing the precision of mood disorder diagnoses, improving treatment outcomes.

Glioma molecular characterization is essential for risk stratification and treatment planning. Noninvasive imaging biomarkers such as apparent diffusion coefficient (ADC) values have shown potential for predicting glioma genotypes. However, manual segmentation of gliomas is time-consuming and operator-dependent. To address this limitation, we aimed to establish a single-sequence-derived automatic ADC extraction pipeline using T2-weighted imaging to support glioma isocitrate dehydrogenase (IDH) genotyping. Glioma volumes from a hospital data set (University College London Hospitals; n=247) were manually segmented on T2-weighted MRI scans using ITK-Snap Toolbox and co-registered to ADC maps sequences using the FMRIB Linear Image Registration Tool in FSL, followed by ADC histogram extraction (Python). Separately, a nnUNet deep learning algorithm was trained to segment glioma volumes using T2w only from BraTS 2021 data (n=500, 80% training, 5% validation and 15% test split). nnUnet was then applied to the University College London Hospitals (UCLH) data for segmentation and ADC read-outs. Univariable logistic regression was used to test the performance manual and nnUNet derived ADC metrics for IDH status prediction. Statistical equivalence was tested (paired two-sided t-test). nnUnet segmentation achieved a median Dice of 0.85 on BraTS data, and 0.83 on UCLH data. For the best performing metric (rADCmean) the area under the receiver operating characteristic curve (AUC) for differentiating IDH-mutant from IDHwildtype gliomas was 0.82 (95% CI: 0.78-0.88), compared to the manual segmentation AUC 0.84 (95% CI: 0.77-0.89). For all ADC metrics, manually and nnUNet extracted ADC were statistically equivalent (p<0.01). nnUNet identified one area of glioma infiltration missed by human observers. In 0.8% gliomas, nnUnet missed glioma components. In 6% of cases, over-segmentation of brain remote from the tumor occurred (e.g. temporal poles). The T2w trained nnUnet algorithm achieved ADC readouts for IDH genotyping with a performance statistically equivalent to human observers. This approach could support rapid ADC based identification of glioblastoma at an early disease stage, even with limited input data. AUC = Area under the receiver operating characteristic curve, BraTS = The brain tumor segmentation challenge held by MICCAI, Dice = Dice Similarity Coefficient, IDH = Isocitrate dehydrogenase, mGBM = Molecular glioblastoma, ADCmin = Fifth ADC histogram percentile, ADCmean = Mean ADC value, ADCNAWM = ADC in the contralateral centrum semiovale normal white matter, rADCmin = Normalized ADCmin, VOI rADCmean = Normalized ADCmean.

The Radiological Society of North America (RSNA) Lumbar Degenerative Imaging Spine Classification (LumbarDISC) dataset is the largest publicly available dataset of adult MRI lumbar spine examinations annotated for degenerative changes. The dataset includes 2,697 patients with a total of 8,593 image series from 8 institutions across 6 countries and 5 continents. The dataset is available for free for non-commercial use via Kaggle and RSNA Medical Imaging Resource of AI (MIRA). The dataset was created for the RSNA 2024 Lumbar Spine Degenerative Classification competition where competitors developed deep learning models to grade degenerative changes in the lumbar spine. The degree of spinal canal, subarticular recess, and neural foraminal stenosis was graded at each intervertebral disc level in the lumbar spine. The images were annotated by expert volunteer neuroradiologists and musculoskeletal radiologists from the RSNA, American Society of Neuroradiology, and the American Society of Spine Radiology. This dataset aims to facilitate research and development in machine learning and lumbar spine imaging to lead to improved patient care and clinical efficiency.

Early and accurate detection of brain abnormalities, such as tumors and strokes, is essential for timely intervention and improved patient outcomes. In this study, we present a deep learning-based system capable of identifying both brain tumors and strokes from MRI images, along with their respective stages. We have executed two groundbreaking strategies involving convolutional neural networks, MobileNet V2 and ResNet-50-optimized through transfer learning to classify MRI scans into five diagnostic categories. Our dataset, aggregated and augmented from various publicly available MRI sources, was carefully curated to ensure class balance and image diversity. To enhance model generalization and prevent overfitting, we applied dropout layers and extensive data augmentation. The models achieved strong performance, with training accuracy reaching 93\% and validation accuracy up to 88\%. While ResNet-50 demonstrated slightly better results, Mobile Net V2 remains a promising option for real-time diagnosis in low resource settings due to its lightweight architecture. This research offers a practical AI-driven solution for early brain abnormality detection, with potential for clinical deployment and future enhancement through larger datasets and multi modal inputs.

Accurate brain tumor classification is essential in neuro-oncology, as it directly informs treatment strategies and influences patient outcomes. This review comprehensively explores machine learning (ML) and deep learning (DL) models that enhance the accuracy and efficiency of brain tumor classification using medical imaging data, particularly Magnetic Resonance Imaging (MRI). As a noninvasive imaging technique, MRI plays a central role in detecting, segmenting, and characterizing brain tumors by providing detailed anatomical views that help distinguish various tumor types, including gliomas, meningiomas, and metastatic brain lesions. The review presents a detailed analysis of diverse ML approaches, from classical algorithms such as Support Vector Machines (SVM) and Decision Trees to advanced DL models, including Convolutional Neural Networks (CNN), Recurrent Neural Networks (RNN), and hybrid architectures that combine multiple techniques for improved performance. Through comparative analysis of recent studies across various datasets, the review evaluates these methods using metrics such as accuracy, sensitivity, specificity, and AUC-ROC, offering insights into their effectiveness and limitations. Significant challenges in the field are examined, including the scarcity of annotated datasets, computational complexity requirements, model interpretability issues, and barriers to clinical integration. The review proposes future directions to address these challenges, highlighting the potential of multi-modal imaging that combines MRI with other imaging modalities, explainable AI frameworks for enhanced model transparency, and privacy-preserving techniques for securing sensitive patient data. This comprehensive analysis demonstrates the transformative potential of ML and DL in advancing brain tumor diagnosis while emphasizing the necessity for continued research and innovation to overcome current limitations and ensure successful clinical implementation for improved patient care.